Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samriddhi Shukla

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 14, 2023
Ultra-high dose-rate proton FLASH improves tumor controlSamriddhi Shukla, Taniya Saha, Nihar Rama, et al.
Molecular Cancer Therapeutics|May 2, 2019
The FOXM1 Inhibitor RCM-1 Decreases Carcinogenesis and Nuclear β-CateninSamriddhi Shukla, David Milewski, Arun Pradhan, et al.
Biologics : Targets & Therapy|March 27, 2023
Demonstration of Safety in Wild Type Mice of npFOXF1, a Novel Nanoparticle-Based Gene Therapy for Alveolar Capillary Dysplasia with Misaligned Pulmonary VeinsFatemeh Kohram, Zicheng Deng, Yufang Zhang, et al.
Nature Communications|May 3, 2023
Lung endothelial cells regulate pulmonary fibrosis through FOXF1/R-Ras signalingFenghua Bian, Ying-Wei Lan, Shuyang Zhao, et al.
Oncogene|February 25, 2021
FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcomaDavid Milewski, Samriddhi Shukla, Berkley E Gryder, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 14, 2023
Ultra-high dose-rate proton FLASH improves tumor controlSamriddhi Shukla, Taniya Saha, Nihar Rama, et al.
Molecular Cancer Therapeutics|May 2, 2019
The FOXM1 Inhibitor RCM-1 Decreases Carcinogenesis and Nuclear β-CateninSamriddhi Shukla, David Milewski, Arun Pradhan, et al.
Biologics : Targets & Therapy|March 27, 2023
Demonstration of Safety in Wild Type Mice of npFOXF1, a Novel Nanoparticle-Based Gene Therapy for Alveolar Capillary Dysplasia with Misaligned Pulmonary VeinsFatemeh Kohram, Zicheng Deng, Yufang Zhang, et al.
Nature Communications|May 3, 2023
Lung endothelial cells regulate pulmonary fibrosis through FOXF1/R-Ras signalingFenghua Bian, Ying-Wei Lan, Shuyang Zhao, et al.
Oncogene|February 25, 2021
FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcomaDavid Milewski, Samriddhi Shukla, Berkley E Gryder, et al.
Pageof 3